A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Objective Response Rate (ORR) Within Dose Subgroup

  Measured over: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months

• Duration of Response (DOR) Within Dose Subgroup

  Measured over: From start date of response (after date of randomization) to first PD, assessed up to 48 months

• Disease Control Rate (DCR) Within Dose Subgroup

  Measured over: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months

• Progression Free Survival (PFS) Within Dose Subgroup

  Measured over: From date of randomization to date of recurrence, progression or death, assessed up to 48 months

• Overall Survival (OS) Within Dose Subgroup

  Measured over: From date of randomization to death, assessed up to 48 months

• Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled Population

  Measured over: From date of first dose through last dose plus 28 days, assessed up to 48 months

Changes Tremor has spotted